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Renin‐angiotensin‐aldosterone	 system	 inhibitors	 (RAASi)	 are	 recommended	 for	





mon	 in	Germany	 (80%)	 and	France	 (77%)	 than	Brazil	 (66%)	 and	 the	United	 States	  
(52%),	where	the	prevalence	of	prescription	decreases	particularly	 in	patients	with	




©	2019	The	Authors.	The Journal of Clinical Hypertension	Published	by	Wiley	Periodicals,	Inc.








































































     |  993PECOITS‐FILHO ET aL.
1  | INTRODUC TION
Given	the	high	prevalence	of	diabetes,	proteinuria,	and	congestive	heart	
failure	 (CHF)	 in	 the	 chronic	 kidney	 disease	 (CKD)	 population,	 clinical	


















scription	of	RAASi	 is	 relatively	 low	 in	 some	patients	with	CKD,	 in	
contrast	 to	 practice	 guidelines	 and	 even	 in	 real‐life	 studies	 based	
in	 academic	 practices.	 The	main	 objectives	 of	 this	 study	 were	 as	
follows:	 (a)	 to	 describe	 RAASi	 use	 in	 the	 Chronic	 Kidney	Disease	






2.1 | Study design and analytic cohort selection
We	conducted	a	cross‐sectional	analysis	of	data	from	the	CKDopps.	
CKDopps	 is	 an	 ongoing	 international	 prospective	 cohort	 study	




CKDopps	 study	 design	 and	 protocol	 details	 have	 been	 published	
previously.6	 The	 ratio	 of	 enrolled	 patients	 with	 eGFR	 <	 30	 mL/




6	months	prior	 to	enrollment,	 if	available.	Routine	 laboratory	data	

















of	 no	 serum	potassium	data;	 and	 an	 additional	 798	patients	were	
excluded	for	no	medication	data,	yielding	a	final	analytic	cohort	of	
5870	patients.
2.2 | Data and statistical analyses
Baseline	 cross‐sectional	 data	 were	 used	 for	 the	 analyses.	
Albuminuria	was	defined	and	classified	 into	 three	categories	 ac‐
cording	to	Kidney	Disease:	 Improving	Global	Outcomes	 (KDIGO)	
2012	 guidelines—normal	 or	 mildly	 increased	 (A1,	 <30	 mg/g),	
F I G U R E  1  Study	flowchart
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moderately	increased	(A2,	30‐300	mg/g),	and	severely	increased	
(A3,	>300	mg/g),	using	spot	or	24‐hour	urine	albumin	or	protein‐
to‐creatinine	 ratio.	 Comorbidity	 data	 were	 supplemented	 with	
medication	use	and	 laboratories	 in	France	 (eg,	HbA1c	and	blood	
glucose	 for	 diabetes)	 and	 determined	 based	 on	 International	
Classification	 of	 Diseases	 (ICD‐10)	 codes	 in	 Germany.	 Standard	
descriptive	 statistics	 (means	 and	 standard	 deviations	 [SDs]	 or	
medians	and	 interquartile	 ranges	 [IQRs]	 for	continuous	variables	
and	frequencies	for	categorical	variables)	were	used	to	report	co‐
hort	characteristics	by	RAASi	use	at	CKDopps	entry	and	country.	
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Mean	 age	was	 66	 years	 in	 Brazil,	 67	 years	 in	 France,	 72	 years	 in	
Germany,	and	68	years	 in	 the	United	States.	The	percentage	with	
CKD	Stage	 4	was	 53%	 in	Brazil,	 42%	 in	 France,	 74%	 in	Germany,	
and	 57%	 in	 the	United	 States.	 The	most	 frequently	 observed	 co‐
morbidities	were	hypertension	 (92%	 in	Brazil,	91%	 in	France,	86%	









States	 (4.50	mEq/L)	 (Table	1).	 Serum	potassium	 levels,	 by	 country	
and	by	CKD	stage,	are	presented	in	Figure	2.	Serum	potassium	lev‐
els	were	higher	 in	more	advanced	stages	of	CKD.	RAASi	prescrip‐
tion	was	more	 common	 in	Germany	 (80%)	 and	France	 (77%)	 than	




by	CKD	 stage	was	 observed	 in	 France	 and	Germany.	 The	 type	of	
RAASi	prescribed	varied	by	countries,	with	ARBs	more	 frequently	
prescribed	 in	 Brazil	 and	 France	 than	 in	 Germany	 and	 the	 United	

































Model 1 Model 2 Model 3
Country	(vs	US)
Brazil 1.27	(1.09,1.49) 1.29	(1.12,1.49) 1.29	(1.12,1.48)
France 1.49	(1.32,1.68) 1.41	(1.25,1.58) 1.44	(1.29,1.62)

















TA B L E  2  Prevalence	ratios	for	RAASia 
prescription	from	modified	Poisson	
models	with	different	levels	of	adjustment


















to	 current	 recommendations,	 RAASi	 was	 prescribed	 in	 a	 limited	
number	of	individuals	of	this	high‐risk	population,	especially	in	the	
United	States	and	Brazil,	even	among	patients	with	strong	class‐















While	hyperkalemia	 is	only	present	 in	2%	of	patients	 treated	
with	 RAASi	 due	 to	 hypertension	with	 apparently	 normal	 kidney	
function,	 the	 incidence	 of	 hyperkalemia	 in	 patients	with	CKD	 is	
substantially	 higher.10	 In	 the	 Irbesartan	 Diabetic	 Nephropathy	








As	 expected,	mean	 serum	 potassium	 increases	 as	GFR	 declines,	
as	does	the	prevalence	of	hyperkalemia,	as	defined	by	serum	po‐
tassium	higher	than	5.5	mEq/L.	Hyperkalemia	was	more	common	
in	Brazil	 than	 the	United	States	 and	Germany;	 several	measures	
used	 to	 control	 hyperkalemia,	 such	 as	 prescription	 of	 diuretics,	
potassium‐binding	 resins,	 and	 bicarbonate	 supplementation,	 as	




of	 diuretics	was	 associated	with	 higher	 prevalence	 of	 RAASi	 pre‐
scription.	 Diuretics	 are	 commonly	 prescribed	 in	 the	 CKD	 popula‐









States	 and	Brazil	 than	 in	Germany	 and	France	 is	 striking,	 and	 po‐
tentially	 instructive.	Higher	RAASi	use	 in	Germany	may	be	 in	part	
due	to	the	substantially	greater	use	of	oral	bicarbonate	and	potas‐
sium‐binding	 resins	 reported	 in	 this	 analysis.	 Additional	 study	 is	
warranted	to	understand	the	effectiveness	of	such	pharmacological	
interventions	in	the	real‐world	setting,	including	longitudinal	follow‐







US	 nephrologists’	 intentions	 to	 prescribe	 RAASi	 to	 as	many	 CKD	
patients	 as	possible,	disjointed	models	of	 care	may	 limit	 achieving	
this	goal.	In	the	primary	care	clinic,	emergency	room,	or	at	hospital	
discharge,	 decisions	may	 be	made	without	 nephrologist	 consulta‐
tion	to	discontinue	RAASi,	or	to	lower	dose,	in	the	face	of	moderate	
hyperkalemia	 or	 small	 increases	 in	 serum	 creatinine	 levels.	 In	 this	







ysis	of	 clinical	decision‐making,	particularly	 related	 to	events	 that	
motivated	changes	in	prescription	prior	to	the	inclusion	of	patients	
in	this	study,	for	example,	discontinuation,	changes	from	dual	to	sin‐
gle	 therapy,	 and/or	dose	 reduction	 that	may	occur	 in	 response	 to	




the	 low	 prevalence	 of	 prescription,	 such	 as	 calcineurin	 inhibitors,	
sulfamethoxazole‐trimethoprim,	 and	 non‐steroidal	 anti‐inflamma‐
tory	agents.
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RAASi	 prescription	 patterns	 in	 CKD	 vary	 by	 country,	 and	 by	
demographic	and	clinical	characteristics.	RAASi	appear	to	be	un‐
derused,	 especially	 in	 the	 United	 States,	 where	 only	 half	 were	
prescribed	 a	RAASi,	 even	 among	patients	with	 strong	 class‐spe‐
cific	 recommendations,	 including	 albuminuria,	 diabetes,	 or	 heart	
failure.	 Higher	 potassium	 levels	 are	 associated	with	 significantly	
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